Drug
Tipiracil clinical trials
- studies test it
- 7
- open now
- 3
- in phase 3
- 2
- first study started
- 2016
Keep track of what changes. Save the tipiracil studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2022 | 1 |
| 2025 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 6
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Centre Georges Francois Leclerc (1) · Institut de Recherches Internationales Servier (1) · Sun Yat-sen University (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Trifluridine (7) · Bevacizumab (2) · Bemarituzumab (1) · Paclitaxel (1) · Ramucirumab (1) · Irinotecan (1) · Vilamakitug (1) · HMPL-013 (1)
Studies
Open first, then newest update. How each study uses tipiracil is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal CancerRecruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT07361003Written as Suvemcitug injection, trifluridine/tipiracil tablets
- Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07261709Written as Trifluridine/tipiracil plus fruquintinib
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal CancerRecruitingPhase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06992648Written as Trifluridine/Tipiracil + Regorafenib
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedPhase 2M.D. Anderson Cancer CenterNCT07011550Written as Trifluridine + Tipiracil
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyActive, not recruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06680622Written as bemarituzumab, trifluridine/tipiracil
- Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, FluoropyrimidineActive, not recruitingPhase 1/2Centre Georges Francois LeclercNCT05201352Written as trifluridine/tipiracil + XB2001
- A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyCompletedPhase 2Institut de Recherches Internationales ServierNCT02743221Written as Trifluridine/tipiracil + bevacizumab
Given in every arm · 2 — tipiracil is usual care beside what is tested
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasRecruitingPhase 1Inhibrx Biosciences, IncNCT03715933Written as Trifluridine + Tipiracil
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminatedPhase 1Astellas Pharma Global Development, Inc.NCT05083481Written as Trifluridine + Tipiracil
As the comparator · 1 — what is tested is compared with tipiracil
Codes
What other systems call tipiracil · ClinicalTrials.gg INT000590
- MeSH (NLM) C000613754tipiracilOne source NLM
- UNII (FDA) NGO10K751PTIPIRACILConfirmed FDA, NLM, Wikidata
- RxNorm 1670304Confirmed FDA, Wikidata
- Wikidata Q21098889tipiracilConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152646TipiracilOne source FDA
- DrugBank DB09343One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000613754 | tipiracil | One source NLM |
| UNII (FDA) | NGO10K751P | TIPIRACIL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1670304 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21098889 | tipiracil | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152646 | Tipiracil | One source FDA |
| DrugBank | DB09343 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.